 Healthline | What's Driving the Surge in Drug Research for "Orphan" Diseases? - Healthline Healthline For example, Biogen Idec's drug Rituximab, a breakthrough treatment for B-cell lymphoma, is projected to generate $34 billion in revenue, according to Thomson Reuters. The drug has since proven helpful in treating rheumatoid arthritis, multiple ... |
